FutureChem Co.Ltd Total Liabilities

Latest as of March 2026: ₩16.93 Billion KRW ≈ $11.47 Million USD

FutureChem Co.Ltd total liabilities. Based on the latest financial reports, FutureChem Co.Ltd (220100) has total liabilities worth ₩16.93 Billion KRW (≈ $11.47 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check FutureChem Co.Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of FutureChem Co.Ltd (2016–2025)

Total liabilities of FutureChem Co.Ltd from 2016 to 2025. This chart illustrates how FutureChem Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore FutureChem Co.Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.

FutureChem Co.Ltd Competitors by Total Liabilities

The table below lists competitors of FutureChem Co.Ltd ranked by their total liabilities.

Company Country Total Liabilities
Maxigen Biotech Inc
TW:1783
Taiwan NT$534.02 Million
Ester Industries Limited
NSE:ESTER
India Rs8.91 Billion
Taseco Air Services JSC
VN:AST
Vietnam ₫298.09 Billion
TMT Investments PLC
LSE:TMT
UK $661.36K
Ubiquoss Inc
KQ:264450
Korea ₩33.78 Billion
DAEYANG ELECTRIC.Co.Ltd
KQ:108380
Korea ₩68.47 Billion
Alcidion Group Ltd
AU:ALC
Australia AU$27.82 Million

Liability Composition Analysis (2016–2025)

This chart breaks down FutureChem Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of FutureChem Co.Ltd.

Liquidity & Leverage Metrics

FutureChem Co.Ltd Total Liabilities Ratios Explained

FutureChem Co.Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 2.54 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.32 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.24 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how FutureChem Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for FutureChem Co.Ltd (2016–2025)

The table below shows the annual total liabilities of FutureChem Co.Ltd from 2016 to 2025.

Year Total Liabilities Change
2025-12-31 ₩19.70 Billion
≈ $13.35 Million
-1.71%
2024-12-31 ₩20.04 Billion
≈ $13.58 Million
+124.71%
2023-12-31 ₩8.92 Billion
≈ $6.04 Million
-52.00%
2022-12-31 ₩18.58 Billion
≈ $12.59 Million
-23.91%
2021-12-31 ₩24.42 Billion
≈ $16.55 Million
-37.52%
2020-12-31 ₩39.08 Billion
≈ $26.49 Million
-24.91%
2019-12-31 ₩52.05 Billion
≈ $35.27 Million
+9.37%
2018-12-31 ₩47.59 Billion
≈ $32.25 Million
+440.85%
2017-12-31 ₩8.80 Billion
≈ $5.96 Million
+458.64%
2016-12-31 ₩1.58 Billion
≈ $1.07 Million
--

About FutureChem Co.Ltd

KQ:220100 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$99.83 Million
₩147.31 Billion KRW
Market Cap Rank
#19037 Global
#909 in Korea
Share Price
₩6570.00
Change (1 day)
-0.30%
52-Week Range
₩5980.00 - ₩34200.00
All Time High
₩34200.00
About

FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products i… Read more